IRVING, Texas, Oct. 14, 2011 /PRNewswire/ -- Reata Pharmaceuticals, Inc. announced Friday a significant expansion of its management team to support the company's lead program, bardoxolone methyl, and to continue advancing its earlier-stage pipeline.
Joining the company are the following executives:
- Paul Audhya, MD, as Vice President of Development and Chief Medical Officer;
- Hilary Malone, Ph.D., as Vice President and Chief Regulatory and Compliance Officer;
- Sean Nolan as Vice President and Chief Commercial Officer; and
- Jim Rouse as Vice President and Chief Information Officer.
The company also announced the addition of Nancy Wysenski -- who is Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals -- to Reata's board of directors.
"This is an exciting period of growth for Reata," CEO Warren Huff said. "Bringing these talented leaders on board is a significant step toward our goal of building a stand-alone, fully integrated biopharmaceutical company."
Paul Audhya, MD, Vice President of Development and Chief Medical Officer. Dr. Audhya joins Reata with over 15 years of biopharmaceutical R&D experience. He led drug development in multiple therapeutic areas, including renal disease, at Johnson & Johnson, The Liposome Company, Bristol-Myers Squibb, Amgen, and Abbott Laboratories. He earned his bachelor's degrees at New York University, his doctorate at New York University School of Medicine, and his MBA from the Graziadio School of Business and Management at Pepperdine University. He completed his residency in internal medicine at the University of Medicine and Dentistry of New Jersey (UMDNJ).
Hilary Malone, Ph.D., Vice President and Chief Regulatory and Compliance Officer. Dr. Malone comes to Reata from Pfizer Inc, where she was Senior Vice President and Head of Worldwide Regulatory Strategy from 2009 to 2011